Regeneron announced that its Phase 3 study of Arcalyst (rilonacept injection) met its primary and secondary endpoints for the prevention of gout attacks. This trial, known as PRE-SURGE 1 (PREventative ...
Kiniksa Pharmaceuticals reports first-quarter results Tuesday before the market opens, with investors scrutinizing whether the biopharmaceutical company can translate strong revenue growth into ...
Kiniksa raised its 2025 ARCALYST net sales guidance to $625 million to $640 million, up from prior guidance of $590 million to $605 million. This reflects management's confidence in continued growth ...
(RTTNews) - Kiniksa Pharmaceuticals Ltd.'s (KNSA) flagship product Arcalyst has garnered widespread acclaim and acceptance since its launch in April 2021. With a growing adoption rate, the company has ...
TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
CEO Sanj Patel highlighted that Kiniksa achieved $137.8 million in net product revenue for ARCALYST during Q1 2025, marking a 75% increase year-over-year. This success was attributed to robust ...
Credit: Getty Images. Arcalyst is a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1. The Food and Drug Administration (FDA) has approved Arcalyst ® (rilonacept) ...
Regeneron Pharmaceuticals saw its stock slip over the weekend after US regulators placed a question mark over the safety of Arcalyst in the gout setting. Regeneron Pharmaceuticals saw its stock slip ...
Tarrytown, NY (August 11, 2008) – Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the publication of the results of three studies which supported the U.S. Food and Drug Administration ...
Kiniksa Pharmaceuticals International (NasdaqGS:KNSA) has launched Heart's Home, a direct to consumer campaign for ARCALYST. The initiative focuses on raising awareness of recurrent pericarditis and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results